JP2010503731A5 - - Google Patents

Download PDF

Info

Publication number
JP2010503731A5
JP2010503731A5 JP2009529215A JP2009529215A JP2010503731A5 JP 2010503731 A5 JP2010503731 A5 JP 2010503731A5 JP 2009529215 A JP2009529215 A JP 2009529215A JP 2009529215 A JP2009529215 A JP 2009529215A JP 2010503731 A5 JP2010503731 A5 JP 2010503731A5
Authority
JP
Japan
Prior art keywords
amino acid
pharmaceutical composition
polypeptide
glycero
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010503731A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/020260 external-priority patent/WO2008036293A1/en
Publication of JP2010503731A publication Critical patent/JP2010503731A/ja
Publication of JP2010503731A5 publication Critical patent/JP2010503731A5/ja
Pending legal-status Critical Current

Links

JP2009529215A 2006-09-19 2007-09-19 肺サーファクタント製剤および粘液クリアランスの促進方法 Pending JP2010503731A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84599106P 2006-09-19 2006-09-19
PCT/US2007/020260 WO2008036293A1 (en) 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance

Publications (2)

Publication Number Publication Date
JP2010503731A JP2010503731A (ja) 2010-02-04
JP2010503731A5 true JP2010503731A5 (enExample) 2010-11-11

Family

ID=38921793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529215A Pending JP2010503731A (ja) 2006-09-19 2007-09-19 肺サーファクタント製剤および粘液クリアランスの促進方法

Country Status (11)

Country Link
US (1) US8221772B2 (enExample)
EP (1) EP2063903A1 (enExample)
JP (1) JP2010503731A (enExample)
KR (1) KR20090060348A (enExample)
AU (1) AU2007297691B2 (enExample)
BR (1) BRPI0717177A2 (enExample)
CA (1) CA2663795A1 (enExample)
MX (1) MX2009003002A (enExample)
RU (1) RU2455021C2 (enExample)
WO (1) WO2008036293A1 (enExample)
ZA (1) ZA200902487B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
EP2211956A4 (en) * 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
EA201300255A1 (ru) * 2010-08-23 2013-06-28 Такеда Гмбх Увлажненные частицы, содержащие терапевтически активное вещество
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) * 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
CA2945604C (en) * 2014-08-08 2022-08-23 Shenzhen Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
WO2017205383A1 (en) * 2016-05-23 2017-11-30 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
US20190231686A1 (en) * 2016-07-16 2019-08-01 Lauranell Harrison BURCH Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
WO2018064529A1 (en) * 2016-09-29 2018-04-05 The Uab Research Foundation Methods and compositions for increasing mucus clearance
WO2018206732A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
US12427273B1 (en) 2020-05-15 2025-09-30 John E. Boyd Methods for treating respiratory distress and compositions for use in the same
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
KR20250153517A (ko) 2024-04-18 2025-10-27 민현홍 신생아 호흡 곤란 증후군을 앓고 있는 조산아의 폐 전달을 개선하기 위한 미세기포 함유 에어로졸
WO2025231023A1 (en) * 2024-04-29 2025-11-06 Virginia Commonwealth University Aerosol surfactant therapy (ast) for respiratory distress syndrome (rds)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840527A (en) * 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989004326A1 (en) 1987-11-04 1989-05-18 California Biotechnology Inc. Alveolar surfactant proteins
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) * 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (en) * 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
ATE231522T1 (de) * 1992-04-10 2003-02-15 Abbott Lab Fragmente eines oberflächenaktiven lungenproteins
US5302481A (en) * 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
PT733645E (pt) * 1993-12-08 2003-07-31 Mitsubishi Pharma Corp Novo peptido sintetico tensoactivo pulmonar que o contem e medicamento para sindroma da insuficiencia respiratoria
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5767068A (en) * 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
JP3819239B2 (ja) * 1998-12-22 2006-09-06 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
RU2149015C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения постнатальных пневмоний у новорожденных
RU2149014C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения острых бронхопневмоний, осложненных ателектазом
DE10006179A1 (de) * 2000-02-11 2001-08-23 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe und Behandlung von chronischen Lungenerkrankungen
US6660833B1 (en) * 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
EP1238680B1 (en) * 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
WO2002092154A1 (en) * 2001-04-26 2002-11-21 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
RU2213746C1 (ru) * 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2198670C1 (ru) * 2002-02-19 2003-02-20 ООО "Биосурф" Способ получения сурфактанта из легких крупного рогатого скота
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
EP1755720A1 (en) * 2004-05-20 2007-02-28 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
EP1781323B1 (en) * 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
CA2579037A1 (en) 2004-08-27 2006-03-09 Discovery Laboratories, Inc. Methods, systems and devices for noninvasive pulmonary delivery
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
ES2380046T3 (es) * 2005-01-06 2012-05-08 Discovery Laboratories, Inc. Régimen para el tratamiento con tensioactivos para tratar o prevenir la displasia broncopulmonar

Similar Documents

Publication Publication Date Title
JP2010503731A5 (enExample)
RU2009114825A (ru) Композиции легочных сурфактантов и способы их применения, содействующие очищению от слизи
JP4651946B2 (ja) 肺病態の治療および予防
JP2019031514A5 (enExample)
JP2005529885A5 (enExample)
JP5405307B2 (ja) 改善された性質を有する再構成サーファクタント
TW201102083A (en) Improved reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
US20230302145A1 (en) Surfactant protein c mimics displaying pathogen- or allergen-binding moieties
KR20230121890A (ko) 섬유증 치료 방법
US12303513B2 (en) Methods and compositions to treat cancer
RU2003108871A (ru) Композиции легочного сурфактанта с режимом динамического набухания
US20070129297A1 (en) Treatment and prevention of asthma
JP2018514564A5 (enExample)
JP2023520917A (ja) 呼吸器状態を処置するためのｔｒｐｃ６阻害剤
CA2827299A1 (en) Liquid propellant-free formulation comprising an antimuscarinic drug
US20170050945A1 (en) Compositions and methods for the treatment of sarcoidosis
WO2014012559A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
CN119156396A (zh) 用于治疗covid感染的方法和组合物
KR20080074085A (ko) 기도에 영향을 미치는 염증 질환에 있어서 조직 인자 경로억제제의 기도 투여법
JP5670006B2 (ja) 去痰剤を含有する医薬組成物
RU2019107379A (ru) Стабильная фармацевтическая композиция, включающая восстановленную композицию легочного сурфактанта
JP5702349B2 (ja) 去痰剤を含有する医薬組成物
WO2013190445A1 (en) Inhalable formulations for removal of viscous secretions from the respiratory tract
WO2004087151A1 (ja) 医薬組成物
HK1184711B (zh) 缓释的抗感染药